MDXH vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MDXH exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -9.30, indicating negative shareholder equity. While the company maintains a strong gross margin (64.55%) and positive revenue growth (~19%), these are completely offset by catastrophic ROE (-2440%) and a consistent track record of missing earnings estimates (0/4 beats in the last year). The technical trend is purely bearish, and the lack of a valid Altman Z-Score combined with poor liquidity ratios suggests a high risk of insolvency.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
MDXH vs MRK: Head-to-Head Comparison
This page compares MDxHealth SA (MDXH) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.